Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of [18F]Fluorthanatrace (FTT) PET/CT in Ovarian Cancer
NCT02637934Phase 1Active, not recruiting
- Sponsor
- Abramson Cancer Center
- Start
- Jan 2016
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of [18F]FluorThanatrace in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Abramson Cancer Center. Primary endpoint: Number of Adverse Events at 3 years. Started Jan 2016; status: active, not recruiting.
02
Drugs
[18F]FluorThanatrace
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02637934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02637934.